ILMN vs LH
Illumina, Inc. and Labcorp, both Healthcare
Illumina, Inc. is the larger company at $27B against $21B. On trailing earnings LH is the cheaper of the two at a P/E of 25.8 against 51.9, a gap that is only a bargain if the two are growing at similar rates. Over the past year ILMN returned +171% against +14% for LH. The RyuScore puts LH ahead, 60 against 36 out of 100.
| Figure | ILMN | LH |
|---|---|---|
| Last close | $278 | $312 |
| Market cap | $27B | $21B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 51.9 | 25.8 |
| Dividend yield | n/a | 0.9% |
| 1-year return | +171% | +14% |
| 5-year return | -36% | +29% |
| RyuScoresector-relative, 1–10 | 36/100 | 60/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Illumina, Inc.
Revenue of $1.2B in Q2 2026, net income $207M. Its largest reported line is United States And Canada, 56% of the disclosed total.
Labcorp
Revenue of $3.7B in Q2 2026, net income $299M. Its largest reported line is Diagnostics, 78% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.